Pall Mall Medical logo

Pall Mall Medical - for all your private healthcare needs, whether you are self-paying or have private medical insurance.

Ovarian Cancer Screening

Private Ovarian Cancer Screening

Book your appointment

Ovarian cancer is the fifth most common cause of cancer-related death among UK women and causes 5% of all cancer deaths in women worldwide. Ovarian cancer can be difficult to diagnose as the symptoms are often similar to other health conditions and include a loss of appetite, frequent urination and bloating, amongst other symptoms. This is one reason why ovarian cancer is often diagnosed at an advanced stage, meaning that a poor survival rate is likely. However, by detecting suspected ovarian cancer early, women are far more likely to survive the illness.

Pall Mall Medical offer two different types of blood tests to help diagnose ovarian cancer:


CA 125 Blood Test

Detection of the CA 125 protein in your blood may indicate the presence of ovarian cancer.

Early detection can increase the rates of survival as only a third of the 6,800 women diagnosed survive for five years. Early detection can increase the survival rate to 90% of women.

While symptoms don't automatically mean you have ovarian cancer, it is advisable to be aware of them and be tested if they don't seem to subside.


HE4 (HE4 and ROMA)

HE4 is a new marker which is over-expressed in patients with ovarian cancer. This test is not currently available on the NHS.

ROMA – A Risk of Ovarian Malignancy Algorithm classifies patients as being at high or low risk for malignant disease using both the CA 125 and HE4 results. It estimates the risk of finding ovarian cancer during surgery.

* When combined with CA 125, this significantly raises the level of sensitivity for the detection.

Which Test is Most Suitable for You?

Recent studies (from the Departments of Obstetrics and Gynecology, and Radioisotope Laboratory at Xuzhou Central Hospital) have shown that, for pre-menopausal women, the combined CA125 & HE4 blood test is more accurate than the single CA125 test for detecting ovarian cancer.
The research is summarised below, with many Consultant Gynaecologists across the world in agreement.
The CA125 test is a standard test within our popular Well Woman Over 45 Health Screen, with the HE4 a popular add-on.

Paper summary:

To assess the ability of human epididymis protein 4 (HE4) and CA-125 to distinguish among benign, borderline, and malignant pelvic masses in premenopausal women.
Of 229 premenopausal patients, 195 (85%) had benign masses, 18 (8%) had EOC, and 16 (7%) had borderline ovarian tumor. The sensitivity of CA-125 and HE4 for EOC detection was 83.3% and 88.9%, respectively. The specificity of CA-125 and HE4 was 59.5% and 91.8%, respectively. A normal HE4 level ruled out invasive cancer in 98% of women with an elevated CA-125.
HE4 offers superior specificity compared to CA-125 for the differentiation of benign and malignant adnexal masses in premenopausal women.

Private ovarian cancer screening prices



CA125 Blood Test

(excludes appointment, from £25)



HE4 Blood Test

(excludes appointment, from £25)



Combined CA125 & HE4 Blood Test

(excludes appointment, from £25)


Ovarian Cancer Health Screen

(includes Gynaecology Consultation, combined CA125 & HE4 Blood test, Ovarian Ultrasound Scan